Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Crohn’s fistulas

- PMLiVE

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease

- PMLiVE

Takeda offers €520m for stem cell firm TiGenix

The deal will go ahead if the Japanese pharma company can secure an 85% stake in the biotech

EU flag

CHMP backs Europe’s first allogeneic stem cell therapy

Takeda has ex-US rights to the Crohn's disease treatment from biotech TiGenix

- PMLiVE

TiGenix’s Crohn’s fistulas treatment wins orphan drug status

FDA designation follows positive trial results

- PMLiVE

Belgium’s TiGenix appoints Dr Gregory Gordon

He takes up a role as head of its US medical development

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

- PMLiVE

TiGenix appoints Dr Marie Paule Richard

She takes on role as chief medical officer and brings experience from Aicuris and Crucell

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links